Mark Landers

Company: Exact Sciences

Job title: Vice President of BioPharma Partnerships

Seminars:

Oncomap ExTra with Xerna TME, Moving Beyond CGP to Better Guide IO Tx Selection 11:05 am

• As immune oncology agents and combinations move through the clinic into practice, more complex biomarker testing is required to effectively guide therapy selection • The Oncomap ExTra germline subtracted whole exome + whole transcriptome with Xerna TME score enables better clinical decision making from a single tumor sample • Reporting Xerna TME phenotype along…Read more

day: day 2 red